Wagner F, Kalusche D, Trenk D, Jähnchen E, Roskamm H
Br J Clin Pharmacol. 1987 Aug;24(2):213-20. doi: 10.1111/j.1365-2125.1987.tb03164.x.
1 The steady-state plasma concentrations of metoprolol and propafenone were determined in patients being treated with one of these drugs alone and during combined treatment with both drugs. In addition, single dose studies with metoprolol, propafenone and the combination of both drugs were performed in healthy volunteers to determine the pharmacokinetics and the time course of beta-adrenoceptor blocking activity. 2 In four patients being treated with metoprolol first and subsequently with propafenone in addition steady-state levels of metoprolol increased two to five fold with simultaneous treatment with propafenone. 3 In four patients being treated with the drug combination first and thereafter with propafenone alone no changes in the steady-state levels of propafenone were observed between both treatment periods. 4 Adverse effects of the drug combination were observed in two patients (one patient experienced severe nightmares and the other left ventricular failure). 5 When single oral doses of metoprolol (50 mg) and propafenone (150 mg) and the combination of both were administered to healthy subjects, an approximately two-fold decrease of the oral clearance of metoprolol was seen when propafenone was given in addition. No conclusive changes in the pharmacokinetics of propafenone could be detected in the presence of metoprolol. 6 Duration of beta-adrenoceptor blocking activity of a single dose of metoprolol in healthy volunteers as measured by reduction of exercise-induced tachycardia increased when propafenone was given in addition. 7 The dose of metoprolol should be reduced when propafenone is given in addition.
1 在单独使用美托洛尔或普罗帕酮其中一种药物治疗的患者以及两种药物联合治疗期间,测定了美托洛尔和普罗帕酮的稳态血浆浓度。此外,在健康志愿者中进行了美托洛尔、普罗帕酮及两种药物联合使用的单剂量研究,以确定药代动力学及β肾上腺素能受体阻断活性的时间进程。2 在4例先接受美托洛尔治疗随后加用普罗帕酮治疗的患者中,美托洛尔的稳态水平在与普罗帕酮同时治疗时升高了2至5倍。3 在4例先接受联合用药治疗随后单独使用普罗帕酮治疗的患者中,两个治疗阶段之间普罗帕酮的稳态水平未观察到变化。4 联合用药组有2例患者出现了不良反应(1例患者经历了严重的噩梦,另1例出现左心室衰竭)。5 当对健康受试者口服单剂量的美托洛尔(50 mg)、普罗帕酮(150 mg)及两者联合用药时,加用普罗帕酮后美托洛尔的口服清除率降低了约两倍。在有美托洛尔存在的情况下,未检测到普罗帕酮药代动力学有确凿变化。6 当加用普罗帕酮时,通过运动诱发心动过速的降低来衡量,健康志愿者单次剂量美托洛尔的β肾上腺素能受体阻断活性持续时间增加。7 加用普罗帕酮时,美托洛尔的剂量应减少。